Low lead levels stunt neuronal growth in a reversible manner by Cline,  H. T. et al.
Proc. Natl. Acad. Sci. USA
Vol. 93, pp. 9915-9920, September 1996
Neurobiology
Low lead levels stunt neuronal growth in a reversible manner
(retinal axons/lead toxicity/visual system development)
HOLLIS T. CLINE*t, SONIA WITrEt, AND KEITH W. JONES§
*Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724; tDepartment of Physiology and Biophysics, University of Iowa, Iowa City, IA 52245; and
§Brookhaven National Laboratory, Upton, NY 11973
Communicated by James D. Watson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY April 19, 1996 (received for review March 21, 1996)
ABSTRACT The developing brain is particularly suscep-
tible to lead toxicity; however, the cellular effects of lead on
neuronal development are not well understood. The effect of
exposure to nanomolar concentrations of lead on several
parameters of the developing retinotectal system of frog
tadpoles was tested. Lead severely reduced the area and
branchtip number of retinal ganglion cell axon arborizations
within the optic tectum at submicromolar concentrations.
These effects of lead on neuronal growth are more dramatic
and occur at lower exposure levels than previously reported.
Lead exposure did not interfere with the development of
retinotectal topography. The deficient neuronal growth does
not appear to be secondary to impaired synaptic transmission,
because concentrations of lead that stunted neuronal growth
were lower than those required to block synaptic transmission.
Subsequent treatment of lead-exposed animals with the che-
lating agent 2,3-dimercaptosuccinic acid completely reversed
the effect of lead on neuronal growth. These studies indicate
that impaired neuronal growth may be responsible in part for
lead-induced cognitive deficits and that chelator treatment
counteracts this effect.
Children exposed to lead, even at concentrations that were
once considered low, have learning disabilities and behavioral
problems (1-3), including deficits in visual system function (4,
5). Two of the major questions regarding lead toxicity concern
the limits of exposure that cause neurological damage in
children and the reversibility of the damage following transient
exposure to lead. The Centers for Disease Control (6) recently
lowered the level of blood lead considered harmful to 10 ,ug per
100 ml ofblood (0.48 MiM); however, the issue of a threshold level
for lead neurotoxicity remains controversial (7, 8).
Calcium disodium-EDTA, a commonly used chelation
agent, reportedly causes a redistribution of lead to the brain
(9). This does not occur following treatment with 2,3-
dimercaptosuccinic acid (DMSA; ref. 10), an orally active lead
chelating agent, which recently received Food and Drug
Administration approval. Although DMSA lowers body lead
burden (11-13), its ability to ameliorate behavioral deficits in
lead-exposed children has not been demonstrated. DMSA is
currently the subject of a double blind clinical study to test its
ability to reverse the effect of lead on cognitive function.
We tested the effect of lead exposure in nanomolar con-
centrations on the following aspects of the development of the
visual projection in frogs: neuronal growth, synaptic transmis-
sion, and the maintenance of topographic retinotectal projec-
tions. We also assessed the ability of the chelating agent DMSA
to reverse the effect of lead exposure on neuronal growth and
compared this to the effect of simply removing the lead source
from the animal.
MATERIALS AND METHODS
Elvax Preparation and Surgical Implantation. Elvax was
prepared and implanted over the optic tectum of Rana pipiens
tadpoles as described (14). Elvax40P (DuPont) was prepared
with stock solutions of 10-4 M-10-8 M lead chloride in 0.1 M
NH4Cl (pH 6.0; 10 ,ul of stock per ml of Elvax) and 10 ,ul of
0.1% fast green prepared with nanopure water. One piece of
Elvax of -250 ,um2 x 30 ,um was surgically implanted under
the dura mater over the pia on the dorsal surface of each tectal
lobe of R. pipiens tadpoles (Taylor and Kollros stage V) under
MS222 anesthesia. Each implanted piece of Elvax weighs -1
mg and contains about 0.1 ,ul of the stock PbCl2 solution. For
the Elvax prepared from 10-4M stock, each milligram of Elvax
contains 2.4 ng of lead. Each animal is implanted with two
pieces of Elvax. Therefore, the maximal lead exposure per
animal over the 6 weeks course of the experiment is -5 ng.
Stage-matched control animals were implanted with Elvax
prepared with vehicle only. For DMSA-Elvax, stock solutions
were prepared in 0.1 M phosphate buffer (pH 7.4). Previous
experiments have shown that this vehicle does not alter
neuronal morphology (14).
Animals were maintained in Nalgene plastic tubs in 0.5%
Instant Ocean (Aquarium Systems, Mentor, OH) and fed
boiled romaine lettuce ad libidum. Tubs were washed twice a
week with 70% EtOH and rinsed in double distilled water.
Lead levels were undetectable in the water by atomic absorp-
tion spectroscopy (AAS; detection limit of 0.5 ppb, for these
samples).
Lead Measurements. Synchrotron radiation-induced x-ray
emission (SRIXE) was used to measure the lead in 1 ,tm-thick
plastic sections of tadpole brains. SRIXE is particularly well-
adapted to this type of measurement because of its low
detection limits and multielement sensitivity (15-18). It can
have a spatial resolution of <10 Am and detection limits as low
as 1 ppm by weight for data accumulation periods of 300 sec.
We were able to detect even lower levels by using longer
analysis times and summing the spectra from different tissue
sections of optic tectal tissue.
The work was done at the X26A x-ray microprobe beamline
of the Brookhaven National Laboratory Synchrotron Light
Source as described (17, 19).. Briefly, the continuous x-ray
energy spectrum from the synchrotron source is used. X-rays
with energies below -4 keV are strongly attenuated by passage
of the beam through a total of 508 Am of beryllium windows.
The beam is defined by a tantalum collimator with an aperture
size of 8 Am. The specimen is placed at a 450 angle to the
incident beam. The beam position is measured using a micro-
scope at 1350 to the beam for normal viewing of the position
of a fluorescent spot on a scintillator. This enables placement
of the beam on any portion of the specimen to an accuracy of
1 ,um. Fluorescent x-rays were detected using an energy-
dispersive Si(Li) x-ray detector with an energy resolution of
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FIG. 1. Nanomolar
concentrations of lead im-
pair the growth of retinal
axons. Examples of retinal
axon arbors from controls
(A) and tadpoles treated
with estimated lead con-
centrations of 10-10 M
(B), 10-9 M (C), 10-8 M(D), 10-7M (E), and 10-6
M (F). For each group of
axons, the arbor on the
left is the largest of the
group drawn, the one on
the right is the smallest
and the middle arbor is
the one closest to the
mean. Lead treatment re-
,100 gim duces the area (G) and
numbers of branchtips
(H) in retinal axon arbors.
Sample size, shown in pa-
rentheses above the bars
in the graphs, refers to the
numbers of axon arbors.
For G and H: *, P < 0.002
and **, P < 0.0005, by a
two-tailed t test.
-160 eV. Detection limits for the apparatus is 10 fg for Pb,
using L-x-ray detection and 10 fg for Zn using K-x-ray detec-
tion (18).
Plastic sections (1 ,um thick) through the optic tectum were
floated onto 7.6 ,um-thick polyimide foils. Specimens were
irradiated for -5500 sec. The resulting spectra were summed
in the two groups and analyzed for lead and zinc content. The
lead spectra were normalized to the zinc readings to control for
inhomogeneities in sample thickness. The Pb/Zn ratio in the
samples treated with lead was twice that in the control
untreated sample. An estimate of the concentration of lead
gave a value of -200 ppb (dry weight) for the lead-treated
specimens and -100 ppb for the control specimens. This
estimate is based on the comparison with a standard of known
areal density, section thickness of 1 ,um, and dry density of 1
g/cm3 for the tissue. Uncertainties in the values for specimen
thickness and density make this only a qualitative estimate;
however, these uncertainties do not play a role when consid-
ering the Pb/Zn ratio. It is important to realize that the value
for the control also serves as an upper limit on background lead
irradiation from the shielded room in which the measurement
was performed, as well as the lead content of the specimen.
Consequently, these values are likely to be overestimates of the
lead content of the tissue. The data collection and analysis
were done blind to the treatment of the specimens.
Lead content in whole brains and eyes was determined by
AAS at the end of the exposure period at the University of
Iowa Hygienic Laboratory with a Perkin-Elmer atomic ab-
sorption spectrometer (model 4100ZL) equipped with a trans-
verse heated graphite analyzer, a microsampling unit, and
Zeeman background correction. Brains and eyes were dis-
sected, frozen on dry ice, and sent to the University of Iowa
Hygienic Laboratory for analysis. Two independent sets of
samples, comprised of tissue from 8-10 animals, were pooled
and analyzed for each lead concentration tested. Frozen tissue
was digested in ultrapure nitric acid and read in duplicate using
standard in 0.5% nitric acid. All samples had spiked recoveries
ranging from 80% to 104%. Lead could only be detected in
tissues exposed to the highest lead levels tested, 50 ng lead,
made from stock solutions of 10-4M PbCl2 in Elvax. There was
no detectable lead in the saline, nor in samples from Elvax
prepared with NH4Cl or 10-6 M PbC12.
Retinal Axon Arbor Morphology. Minutin pins tipped with
horseradish peroxidase (HRP) were inserted at several sites in
the retina under MS222 anesthesia as described (14). Two days
later, animals were terminally anesthetized and their brains
were processed for HRP histochemistry. The optic tecta were
cut away from the brain, flattened between coverslips, and
fixed. Each optic tectum was assigned a number, and the
remainder of the data collection and analysis was performed
blind to the treatment. Labeled class 3 retinal ganglion cell
(RGC) axons, which are located 100-200 ,um below the pial
surface, were drawn with a camera lucida using a x63 oil
immersion lens. Branchtips were counted from the drawn
arbors. Arbor areas were determined from the number of
pixels covered by a scanned image of the arbor using the
Universal Imaging (Media, PA) IMAGE 1 software. Once the
blind was broken, it was clear that exposure to lead does not
appear to interfere with HRP labeling of RGC axons. Com-
parable numbers of labeled axons and staining intensity were
achieved in the control and experimental animals. Axons from
three to seven animals per treatment group were analyzed.
Retinotectal Topography. Animals were implanted with
lead-Elvax prepared with 10-3 M, 10-4 M, and 10-5 M PbCl2
stock (two animals for each concentration). Two months later,
the optic tectum was exposed and the position of the Elvax over
the tectum was verified. HRP (20% in water) was injected
focally into the rostromedial optic tectum using a General
Valve (Fairfield, NJ) Picospritzer. After 5 days, the brains and
retinae were processed for HRP histochemistry. The tecta and
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retinae were flattened between coverslips and fixed. The area
of the retina in which HRP-labeled RGCs were located was
measured using Universal Imaging IMAGE 1 software and
compared with stage-matched, sham-operated tadpoles. No
differences were seen in the labeled areas for the three lead
concentrations, so the data were pooled.
Electrophysiology. Animals between stages V and X were
anesthetized in 0.05% MS222. Brains including -3-mm optic
nerve were removed and placed in a recording chamber under
constant perfusion with saline solution (100 mM NaCl/2 mM
KCl/2.5 mM MgCl2/1.5 mM CaCl2/5 mM glucose, buffered to
pH 7.4 with bicarbonate and CO2). The dura overlying the
optic tectal lobes was removed and the brain was split along the
dorsal midline and secured with minutin pins. The optic nerve
was stimulated through a glass suction electrode and excitatory
postsynaptic currents were recorded from tectal neuronal cell
bodies using patch pipettes of 7-10 MQl resistance filled with
100mM cesium gluconate, 0.2mM EGTA, 5mM MgCl2, 4mM
Na-ATP, 0.3 mM GTP, 40 mM Hepes (pH 7.2) with CsOH.
Concentrated solutions of lead chloride in 0.1 M NH4Cl were
added to the perfusion solution to give the final concentrations
listed in the text and figures. The highest concentration of
NH4Cl in the perfusion solution was 1 mM. Addition of NH4Cl
to the perfusion solution did not significantly change the
amplitude of synaptic responses.
RESULTS
Lead was delivered to the brains of R. pipiens tadpoles using
implants of the slow release plastic polymer, Elvax, which
releases low molecular weight compounds at a constant low
rate over a period of several months (14, 20). Elvax has been
used extensively to provide controlled and sustained release of
a wide variety of bioactive molecules, including neurotrans-
mitters, receptor and channel antagonists, enzymes, polypep-
tides, steroid hormones, and growth factors (20-25). It pro-
vides the advantage of direct exposure of the brain to lead or
DMSA, thereby eliminating concerns of changes in uptake,
clearance, or distribution during the experiment. Lead appli-
cation by Elvax also minimizes the amount of toxic lead in the
laboratory and environment.
Lead content in the optic tectum of animals exposed to 5 ng
of lead for 6 weeks was measured using SRIXE. SRIXE is a
quantitative method to analyze trace elements in tissue with
spatial resolution <10 ,um and detection limits as low as 1 ppm
by weight (15-18). SRIXE is ideal for lead detection in small
tissue samples. By repeatedly scanning sections of tadpole
optic tectum (see Materials and Methods), we were able to
detect even lower lead levels of 200 ppb (dry weight) lead in
tadpoles exposed to 5 ng of lead in Elvax. We were unable to
detect lead in tissue exposed to 5 ng of lead in Elvax using AAS
due to the small mass of the sample and low lead levels.
To study the effect of lead exposure on the development of
neuronal structure, we examined HRP-labeled retinal ganglion
cell axon terminations (arbors) following 6 weeks of exposure
of the optic tectum to lead-Elvax. Retinal axon arbors exposed
to 5 ng-5 pg total lead in Elvax for 6 weeks were reduced in
size to between 12% and 25% of the area of sham-operated
control axon arbors. These axon arbors also had correspond-
ingly fewer branchtips (P < 0.0005, two-tailed t test; Fig. 1).
Exposure to 0.5 pg of lead in Elvax resulted in a significant
decrease in branchtip number; however, arbor area was not
significantly reduced compared with controls (P < 0.002).
These data suggest a threshold for the effect of lead on these
parameters of neuronal development. Exposures to increasing
amounts of lead showed greater reductions in arbor area and
branch number. The reduction in arbor area and branch
number appears to level off at the higher lead concentrations
tested, suggesting that the mechanism by which lead impairs
neuronal growth becomes saturated. Despite the reduced
arbor area and branch numbers, the majority of the branches
are tipped by growth cones with wide lamellapodia and
numerous filopodia (Fig. 1 C-F). Lamellar growth cones are
more likely to be in a nonmigratory, exploratory mode, rather
than rapidly extending (26). The increased prevalence of
lamellar growth cones suggests the lead exposure may have
altered the extracellular environment in the tectum (27, 28).
To estimate exposure levels of lead to the brain, we assumed
that the lead is released into a volume equivalent to that of the
brain. This is supported by two independent measures. First,
we compared the total lead content of the brain and the eyes
of animals in which Elvax was implanted over the brain, while
the eyes had no contact with the Elvax. The lead content of the
eyes (3.9 ± 0.38 ,ug per g) was comparable to the lead content
of the brain (4.5 ± 0.46 jig per g) after 6 weeks of exposure of
the brain alone to lead-Elvax containing 50 ng of lead. These
data indicate that comparable amounts of lead are accumu-
lated throughout the brain and eyes.
Second, we tested for a possible gradient of effective lead
concentration originating from the Elvax implant by plotting
the area of lead-treated arbors as a function of the distance of
the center of the axon arbor from the Elvax implant in the
tectum (Fig. 2). The Elvax was implanted over the dorsal optic
tectum. Axons in the lateral tectum may be as far as 2 mm from
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FIG. 2. Effective exposure levels of lead are uniform across the
optic tectum. (A) Diagram of the dorsal midbrain region of the tadpole
brain showing the caudal thalamus, the bilateral optic tectal lobes, and
rostral spinal cord. The dark box in the left tectal lobe represents the
position of one Elvax implant. The implant over the right tectum is not
shown. The light box in the medial thalamus shows the position of an
Elvax implant recovered from one animal. The data corresponding to
the axons from this animal are shown in C in open squares. (B)
Diagram of the left optic tectum that has been dissected from the brain
and flattened. The dotted lines are shown at 500-,um intervals irra-
diating from the center of the Elvax implant, which is shown as the box.
The two axons, the box, and the tectum are drawn to scale to show that
axons immediately under the Elvax are not more severely effected by
the lead than axons as far as 2 mm from the Elvax. R, rostral; M,
medial; L, lateral; C, caudal. (C) No correlation exists between the size
of the axon arbor and the distance of the axon from the Elvax implant.
Data compiled from animals treated with lead-Elvax at 10-6 M-10-9
M are shown in filled squares. Data from animals treated with 10-10
M lead are shown in open diamonds. The open squares are data from
two axons drawn from an animal in which the Elvax was recovered over
the thalamus, at distances of 1 and 2mm from the reconstructed axons.
R = -0.21, P > 0.55 for all data pooled; R = -0.05, P > 0.74 for the
lowest lead concentration tested. If a gradient in the effective lead
concentration existed in the optic tectum, it would be most easily seen
in these data, where the effect of lead on axon arbor area was the least
dramatic of the concentrations tested. Nevertheless, axons that were
the farthest from the implant are among the smallest axons in this
group.
Neurobiology: Cline et al.
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the lead source. The type 3 retinal axons analyzed here are
-200 ,um below the pial surface of the tectum. Therefore,
axons may be as close as 200 ,tm and as far as 2000 ,tm from
the Elvax implant. If lead were to diffuse out of the Elvax and
be rapidly accumulated by neurons close to the implant (29),
one might expect to see a greater effect of lead exposure on
axons close to the Elvax compared with those farther away.
Such an effect of distance on arbor size should be most easily
seen with the lowest lead concentration. There is no correla-
tion between the arbor area and the distance of the axon from
the Elvax implant, even at the lowest concentration of lead-
Elvax (R = 0.05, P > 0.74 by Spearman nonparametric test of
association). Taken together, these data suggest that the effective
lead levels that alter neuronal growth are comparable throughout
the optic tectum. In addition, the data support the idea that lead
is released into a volume equivalent to the brain cavity.
Assuming that all the lead in the Elvax is released into a
closed volume equivalent to the brain volume of 25 ,lI (i.e.,
assume that no lead is cleared from the tissue during the
experiment), then 5 ng of lead in Elvax would correspond to
1 ,uM extracellular exposure concentration. Based on this
estimate, our data show that exposure to 1 nM lead signifi-
cantly impairs neuronal growth. This value is likely to be an
overestimate of the extracellular ionic lead concentration,
because it does not take into consideration factors that are
known to decrease the levels of toxic free lead. In particular,
both the binding of lead to extracellular and intracellular
proteins as well as the accumulation and precipitation of lead
into intracellular organelles (29) reduces ionic lead concen-
trations several-fold (30).
The capacity of DMSA to reverse the effect of lead on
retinal arbor growth was tested in the following experiment.
Animals were treated for 6 weeks with 50 pg of lead (10-6 M
lead chloride stock in Elvax). Some animals were processed
immediately to assess the effect of lead on arbor morphology.
The remaining animals were divided into four groups. In two
groups, the lead-Elvax was removed and replaced with either
DMSA-Elvax (10-5 or 10-4 M) or Elvax prepared with the
phosphate buffer vehicle for 4 weeks. In the other group, the
lead-Elvax was removed and the animals were left to survive
with no further treatment for 4 weeks before retinal axon
morphology was assayed to test the possibility that axon
A X
morphology could recover in the absence of lead or chelator.
Axons from a final group of animals were treated only with
DMSA for 4 weeks.
The results indicate that the effect of lead on arbor mor-
phology can be reversed by subsequent treatment with DMSA
for 4 weeks (Figs. 3 and 4). Axons that were exposed to lead
followed by a 4-week period without DMSA treatment showed
partial recovery of normal arbor morphology (Fig. 3E). Ex-
posure to the phosphate buffer vehicle alone did not result in
greater recovery of normal axon morphology than simple
removal of the lead-Elvax. The axon arbors from animals that
were exposed to lead and left for 4 weeks without further
treatment are significantly smaller than controls (P < 0.01) and
have fewer branchtips (P < 0.0001; Fig. 4). When compared
with the lead-treated arbors from animals with no recovery
period (Fig. 3B), they are significantly larger (P < 0.0002) and
have more branchtips (P < 0.001). Treatment with chelator
alone does not significantly alter arbor morphology (Fig. 3D),
indicating that the chelator itself does not impair the cellular
mechanisms controlling neuronal growth.
To test the effect of lead on synaptic transmission, whole cell
patch clamp recordings of retinotectal synaptic currents were
taken from an isolated brain preparation. Lead (10 ,uM-10
nM) was applied by perfusion while recording synaptic cur-
rents from normal tectal neurons held at -55 mV holding
potential in response to electrical stimulation of the optic
nerve. Lead (10 nM) blocked postsynaptic currents by 16.9 ±
3.4%, whereas 60% of the current was blocked by the addition
of 10 ,M lead in the perfusion solution (Fig. 5). The decrease
in synaptic transmission at higher lead concentrations is most
likely due to block of voltage-sensitive calcium channels
(VSCCs) required for transmitter release, as has been ob-
served in mammalian (31-33) and nonmammalian neurons
(34). It is unlikely that the change in arbor morphology we
observe is due to lead blocking VSCCs and synaptic transmis-
sion because tetrodotoxin, which indirectly blocks VSCCs and
retinotectal synaptic transmission, results in enlarged retinal
axon arbors (22).
The formation of accurate topographic sensory projections
represents one aspect of the brain's capacity to develop
organized projections between different regions of the brain.
Based on extensive work on the development of topographic
c
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FIG. 3. DMSA treatment
reverses the effect of lead ex-
posure on arbor morphology.
Examples of retinal axons af-
ter the following treatments:
sham-operated controls (A),
10-8 M lead for 6 weeks (B),
10-8 M lead for 6 weeks fol-
lowed by DMSA for 4 weeks
(C), DMSA alone (D), and
10-8 M lead for 6 weeks fol-
lowed by 4 weeks without lead
or DMSA (E). For each treat-
ment, the arbor on the left is
the largest of the group
drawn, the one on the right is
the smallest, and the middle
arbor is the one closest to the
mean, except inA and B. For
these cases, different exam-
ples were chosen than those in
Fig. 1 to show a broader sam-
ple of the data.
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FIG. 4. Quantification of the effect of DMSA on arbors. DMSA
reversed the effect of lead exposure on retinal arbor area (A) and
numbers of branchtips (B). Sample size, shown in parentheses above
the bars in the graphs, refers to the numbers of axon arbors. No
difference was seen in the effect of treating with 10-4 M or 10-5 M
DMSA, so the data from the two groups were pooled. (A) *, P < 0.01
compared with control and P < 0.0002 compared with the lead-treated
arbors. (B) **, P < 0.0005 compared with controls and P < 0.001
compared with the lead-treated arbors by a two-tailed t test.
maps, many cellular mechanisms required for their develop-
ment are known (35, 36). Development and maintenance of
the topographic retinotectal projection in tadpoles requires
retinotectal synaptic transmission, activation of postsynaptic
N-methyl-D-aspartate (NMDA) receptors, and the migration
of axon arbors within the tectal neuropil (35, 36). An assay of
retinal topography in lead-treated animals therefore provides
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FIG. 5. Effect of increasing lead concentrations on retinotectal
synaptic transmission. Whole cell recordings from tectal neurons were
taken at a holding potential of -55 mV during electrical stimulation
of the optic nerve. Peak amplitudes of evoked excitatory postsynaptic
currents for each neuron were determined from the average of =500
sweeps for each concentration of lead. The means and standard error
of averaged peak responses are shown. The open circle shows the peak
synaptic current with 1 mM NH4Cl in the saline recorded from two
neurons. For 10-8 M, n = 7; for 10-7 M, n = 6; for 10-6 M, n = 5;
and for 10-5 M, n = 4. (Inset) Examples of synaptic currents recorded
under control conditions and in the presence of increasing concen-
trations of lead. The dashed line is control; the solid line is in the
presence of the designated molar concentration of lead chloride.
Averages of 500 sweeps.
an in vivo test of the integrity of these aspects of neural
function. If lead blocks any one of them, then it would be
detected as a disruption of retinal topography. Micromolar
concentrations of lead block retinotectal synaptic transmission
(Fig. 5). In other systems, micromolar concentrations of lead
block the NMDA-type of glutamate receptor (37) and VSCCs
(31, 33, 34) and thereby decrease or block synaptic transmis-
sion (32). To test whether the lead exposures that impair
neuronal growth in vivo are sufficiently high to block synaptic
transmission or NMDA receptor activity, we assayed the effect
of lead exposure on the maintenance of the retinotectal
topographic projection. If the lead exposures that alter retinal
arbor morphology result in micromolar concentrations of lead
in vivo, then this should block synaptic transmission and
NMDA receptors and disrupt retinal topography. If the lead
exposures that alter retinal arbor morphology have no effect
on retinal topography, then this is consistent with the inter-
pretation that submicromolar concentrations of lead in vivo
impair neuronal growth.
No difference in retinotectal topography was seen between
the controls and lead-treated tadpoles. The retinal area cov-
ered by the labeled RGCs was 4.25 ± 1.05% of the total retinal
area in the control animals and 5.42 ± 0.91% in the lead-
treated animals (n = 6 for each). These values are not
significantly different. For comparison, blocking tectal cell
NMDA receptors increases the retinal area covered by labeled
RGCs to 20% of the total retinal area (14). These data indicate
that the in vivo lead treatments used in these studies do not
blockNMDA receptors and do not grossly disrupt the patterns
of retinotectal synaptic transmission which are required for the
maintenance of retinal topography. This is consistent with the
estimated concentration of lead in the tectum being lower than
that required to block NMDA receptors (37). The data further
suggest that these lead exposures do not impair the ability of
the brain to develop topographic projections per se, even
though the axonal projections that develop are deficient.
Indeed, as has been shown in previous studies (38) treatments
that decrease the size of the arbor do not necessarily disrupt
retinal topography.
DISCUSSION
The present data indicate that lead can cause gross morpho-
logical defects at submicromolar concentrations. The dramatic
stunting of arbor morphology seen after 6 weeks is likely the
cumulative result of a gradual decrease in arbor area and the
number of branchtips. In vivo time-lapse imaging of growing
RGC arbors has shown that branches are constantly added and
retracted from the arbor (39). Only a fraction of the newly
added branches are maintained and contribute to the net
growth of the arbor. In principle, lead could reduce arbor area
and branch number by decreasing the rate of branch additions
or by increasing the rate of branch retractions (36). Based on
the observation that retinal topography is not disrupted by lead
exposure, lead does not appear to interfere with branch
additions or arbor migration. We suggest that lead is more
likely to increase the rate of branch retractions.
The effect of lead on neuronal morphology that we and
others (40-45) observe may be due to impaired assembly or
stability of the cytoskeleton (46). Our interpretation is con-
sistent with the ability of lead to interfere with calcium-
dependent events (47) including calcium-sensitive protein
kinases (48-50), which have been implicated in neuronal
growth in a variety of neurons (51-54), including frog retinal
axons (38, 55).
The dramatic loss in axon arbor area and branchtip number
necessarily means a reduction in the number and spatial
distribution of the postsynaptic partners that each retinal
ganglion cell axon contacts. Such a change in the normal
degree of convergence and divergence of visual information in
the optic tectum is consistent with the idea that the reported
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impairment in visual processing following lead exposure (56,
57) may be at least partially due to defects in neuronal growth.
DMSA is required to accomplish full recovery of normal
axon morphology following lead exposure, whereas simply
removing the lead-Elvax results in partial recovery. This
indicates that the mechanisms concerned with neuronal
growth are affected even after the source of lead is removed
from the animal. One possible reason is that lead is harbored
in the optic tectum. The optic tectum of frogs stains intensely
for Timms reaction, which classically reveals anatomical re-
gions of high zinc content; however, regions rich in endogenous
zinc also accumulate environmental lead (58). The data sug-
gest that DMSA reduces lead content and permits recovery of
neuronal morphology and are consistent with the idea that
DMSA may decrease intracellular lead levels.
In summary, exposure to nanomolar lead stunts the growth
of retinal ganglion cell axonal projections within the central
nervous system, but it has no apparent effect on the topo-
graphic organization of the retinotectal projection. The inte-
gration ofvisual information is likely to be abnormal due to the
reduction in the numbers of retinal afferents that contact each
tectal neuron. This in turn may result in more generalized
deficits in neural function. The magnitude of the effect of lead
on neuronal morphology reported here is greater than previ-
ously reported in other systems and occurs at lower lead
concentrations than previously tested. Previous studies have
shown that amphibians and mammals employ similar cellular
mechanisms during nervous system development (35). There-
fore, impaired neuronal growth may contribute to lead-
induced cognitive deficits in humans. Finally, treatment with
DMSA is highly effective at reversing the effect of lead
exposure on neuronal growth.
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